Breast Cancer Biomarkers

Primary carcinoma of the breast is the most common type of breast malignancy. Breast cancer is diagnosed by breast biopsy or excision and is then subsequently staged. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) biomarker testing is performed to establish hormone receptor status, which provides both prognostic and predictive value. Women with early-stage invasive breast cancer and known ER+/PR+/HER2- status may then benefit from prognostic biomarker panels that can provide information to guide decisions about adjuvant systemic therapy. Individuals suspected of hereditary cancer risk may also undergo testing for pathogenic variants (mutations) commonly associated with breast cancer, including variants in BRCA1 and BRCA2 genes.

Tabs Content
Content Review: 
March 2019

Last Update: January 2020